RedHill Biopharma inks US commercialization deal for GI product

Israel-based biotech RedHill Biopharma (TASE: RDHL) has entered into a commercialization agreement with ParaPRO, an Indiana-based specialty pharmaceutical company, granting RedHill the exclusive rights to promote Esomeprazole Strontium Delayed-Release Capsules to gastroenterologists in certain US territories.

Esomeprazole Strontium DR Capsules 49.3mg is a prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD), risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence and for pathological hypersecretory conditions, including Zollinger-Ellison syndrome. Esomeprazole Strontium DR Capsules 49.3mg is a proprietary prescription drug approved by the FDA under a New Drug Application.

RedHill’s US commercial operations, headquartered in Raleigh, NC, include a gastrointestinal (GI)-focused sales force of 40 sales representatives promoting Donnatal (phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide) and EnteraGam (serum-derived bovine immunoglobulin/protein isolate, SBI) in select US territories.